Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
@leave the gun... Yes it does.
You do realize that the reason Ab8 had to be tested in animals is because it has not gone through a Phase 1 trial to establish safety in humans. Brilacidin has an established safety profile in humans and has established efficacy and safety in multiple human cell lines. I prefer our situation to theirs.
Lemoncat said,
Again, you are wrong. The company has already publicized that it is advancing Brilacidin against Covid in a Phase 2 trial. That means humans, not animals. The reason (again) is that animal testing is primarily to determine safety. Efficacy results (positive or negative) for a particular drug in animals often does not translate to humans, so the “fruitless” testing would be if we did an animal trial. Thankfully, Leo is smart enough not to waste our money on “fruitless” animal testing.
Lemoncat said,
Leo! Stay the hell away from that crook! He cannot be trusted.
We’d be much better off if he interviewed with Dr. Oz rather than Cramer.
MrGlasses said,
Again, this step is not necessary once safety in humans has been established.
Lemoncat said,
Brilacidin is way past the “mice and hamster” stage. You don’t have to go back and repeat animal testing for every disease. Animal testing is done to determine drug safety. We are long past that. Next up for Brilacidin vs Covid is Phase 2 in humans.
Lemoncat said,
Exactly! We don’t need no stinking Remdesivir...
WarrenThomas said,
Is the FDA application waiting on that pre-print to come out? It’s time for the RBL to put together that pre-print based on what they have already accomplished. Hopefully they are in the process of writing it up while testing continues. If for some reason they can’t write and test, then maybe it’s time for the writing to take priority. In this case, Remdesivir adds no significant benefit and lowers the safety profile. I hope the pre-print was not delayed for the Remdesivir testing.
From the PR,
You are in my prayers. Hurry back!
Understood and mission accomplished!
Thanks KarinCA but I’m not a Tweeter.
This is a very well researched and well written article. If there was an email link for Dhruv Khullar, I would write him and tell him so. (I would also put in a plug for Brilacidin and attach a few links to some PRs while I was at it...).
https://apple.news/AlL5mKEKrTIS0f5rp2a_igw
ROTFLMAO!
FatAlbert said,
Thank you both.
Does anyone still have the name and phone number for that Bankruptcy trustee?
Thank you. That’s a much better response than name calling. And by the way, “your welcome”. I’m glad I was able to give you the opportunity to clarify what some otherwise might have interpreted as anti-Semitic. After all, the “Loanranger” and Tanto were all about diversity...
Hell no...
Zandant said,
I believe Kevetrin and Brilacidin will each eventually exceed $5 billion annually. If IPIX goes it alone, that $10 billion in revenue, with a multiplier of 20, generates a market cap of $200 billion or ~$600 per share. Of course there will be a lot of water under the bridge before that comes to pass. Would the time value of money be worth the risk and the wait?
PJ007 said,
What are you talking about?
Codebreaker said,
Very interesting video...
https://vimeo.com/419712751
We have all been wondering how this company could fail with a product that WORKS so very, Very, VERY, WELL! Watch this video to see who stole our money and killed our company. We already know about
Knight Capital’s shenanigans. This video list six more major players including Goldman Sachs and JP Morgan.
https://vimeo.com/419712751
There might actually be a multi-trillion dollar class action lawsuit coming so you might want to also visit the website and sign up for free updates.
www.stopnakedshortselling.org
I don’t think so. I’d consider $50 million up front and 50% of the gross on the back end...
BlueFin said,
Krishna Menon? That name sounds familiar...
Kevetrin induces apoptosis in TP53 wild-type and mutant acute myeloid leukemia cells
ROBERTA NAPOLITANO 1, SERENA DE MATTEIS 1,7, SILVIA CARLONI 1, SAMANTHA BRUNO 2, GIULIA ABBATI 1, LAURA CAPELLI 1, MARTINA GHETTI 1, MARIATERES ABOCHICCHIO 1, CHIARA LIVERANI 1, LAURA MERCATALI 1, DANIELE CALISTRI 1, ANTONIO CUNEO 3, KRISHNA MENON 4, GERARDO MUSURACA 5, GIOVANNI MARTINELLI 2,6* and GIORGIA SIMONETTI 1*
Perhaps a signal between the market makers?
TheDane said,
Oh I think it’s much more likely than that. I put the odds at more like 1 chance in 40,000... ??
Here Today said,
Actually, I think Brilacidin alone is worth much, MUCH more than $9 per share.
ZROYPU said,
Is this what happened to RCPI?
Part 1...
https://theintercept.com/2016/09/22/the-money-is-gone/
Part 2...
https://theintercept.com/2016/09/23/big-players-little-stocks-and-naked-shorts/
Part 3...
https://theintercept.com/2016/09/24/naked-shorts-cant-stay-naked-forever/
Part 4...
https://theintercept.com/2016/09/25/calling-the-sec/
Part 5...
https://theintercept.com/2016/09/26/turning-up-like-a-bad-penny/
Part 6...
https://theintercept.com/2016/09/27/were-paper-losses-the-goal-all-along/
Part 7...
https://theintercept.com/2016/09/28/the-half-billion-dollar-glitch/
Has this been happening to IPIX?
Part 1...
https://theintercept.com/2016/09/22/the-money-is-gone/
Part 2...
https://theintercept.com/2016/09/23/big-players-little-stocks-and-naked-shorts/
Part 3...
https://theintercept.com/2016/09/24/naked-shorts-cant-stay-naked-forever/
Part 4...
https://theintercept.com/2016/09/25/calling-the-sec/
Part 5...
https://theintercept.com/2016/09/26/turning-up-like-a-bad-penny/
Part 6...
https://theintercept.com/2016/09/27/were-paper-losses-the-goal-all-along/
Part 7...
https://theintercept.com/2016/09/28/the-half-billion-dollar-glitch/
I used to be the Executive Director of a non-profit and my Deputy Director was a retired Air Force Colonel. He suffered from Ulcerative Colitis. He once told me that his UC medicine was costing TriCare $20,000 per month. I think a treatment for UC that works will bring in billions in annual sales. I see the initial price point for Brilacidin (for pretty much every indication) to be at least one to two thousand dollars per treatment.
HereToday said,
Once Brilacidin proves itself in a human trial, I expect that there will be a government contract to purchase a few million doses. At that point, we will not need a BP. If Leo decides later to get someone to do marketing and distribution, he should be able to get that done for a small percentage, maybe 10% or 20% of the gross. BPs get a big cut when they assume a big chunk of the upfront risk. If IPIX can fund all of our drug development, BP loses virtually all of the possible leverage they could have had in the negotiations.
HereToday said,
I would think that there almost needs to be two trials. One focused on late stage patients and one where B is administered earlier to prevent the “late stage” from ever occurring. Or could these two be accomplished with the same trial?
SolidStrategist said,
Cellceutix is not “defunct”. Cellceutix simply changed its name to Innovation Pharmaceuticals (IPIX). It is the same company.
PlentyParanoid said,
I think that you will find this article in The Economist to be very much on point. For example, the “Excess Deaths” over historical norms in the US for the period of March 7 - July 31 was 214,812. The deaths attributed to Covid-19 for that period is only 152,611. That is 62,201 additional “Excess Deaths” that were not attributed to Covid-19. Again, thanks to Drano on The Other Board for finding this article.
https://www.economist.com/graphic-detail/2020/07/15/tracking-covid-19-excess-deaths-across-countries
TheDane said,
Thank you. Please see my post # 321593. I think you will find it interesting.
Several of you have responded to my request for assistance and I thank you all. Here is an interesting article from The Economist on the Covid-19 death rate that seems most on point. It compares the expected death rates based on previous years historic data, to the actual death rates experienced this year. The actual death rate is of course higher than it has been historically but it is actually higher than the number of deaths being reported as due to Covid-19. Since some are saying that the Covid-19 death rate is being over-reported, I thought this article was very interesting.
Credit to Drano on The Other Board for the link below.
https://www.economist.com/graphic-detail/2020/07/15/tracking-covid-19-excess-deaths-across-countries
Condolences... We recently lost my wife’s Aunt to Covid-19. Let’s hope that Brilacidin will soon help the world put this disease behind us.
I agree. But I have those among my family and friends who don’t agree and I would like to convince them otherwise. That’s why I am looking to make relevant multi-year comparisons of the overall death rate by month. I expect that data to show that this year’s overall monthly death rate is higher due to Covid-19. That data for the State of NY and the country of Italy might be particularly informative.
Morfeyus said,
I am looking to compare the overall US death rate month by month for this year compared to years past. I would also particularly like to make this comparison for the state of NY. Another such interesting comparison may be the country of Italy. I think that such comparisons might be a good way to cut through the BS and perhaps more accurately measure the real impact of Covid-19. Does anyone know where this information may be sourced?
From Blufin’s post:
I think that B-OM should qualify because some people cannot complete their Chemo or Radiation regimen due to the severity of the OM. OM is already serious but that makes it life threatening.
Dreamer0 said,
Does anyone know why going direct to a Phase 4 trial would not be appropriate for B-OM? There is much suffering and no real treatment. Why not do a Phase 4? Does a Phase 4 require an EUA? As I understand it, the company could even charge for the treatment and thus generate funding for the trial and operations.
tduggan said,